vs
CANTALOUPE, INC.（CTLP）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
CANTALOUPE, INC.的季度营收约是PUMA BIOTECHNOLOGY, INC.的1.0倍（$78.7M vs $75.5M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs 6.8%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $-614.0K），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs 7.7%）
坎塔卢波（原美国技术公司）是一家美国科技企业，核心业务为ePort无现金支付受理技术，依托持专利的PCI合规ePort Connect服务开展运营。该服务可通过无线方式为消费者提供信用卡、借记卡以及Apple Pay、Google Pay等NFC钱包支付选项，同时为运营商提供遥测与机器间通信服务，ePort技术主要应用于...
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
CTLP vs PBYI — 直观对比
营收规模更大
CTLP
是对方的1.0倍
$75.5M
营收增速更快
PBYI
高出21.0%
6.8%
自由现金流更多
PBYI
多$15.0M
$-614.0K
两年增速更快
PBYI
近两年复合增速
7.7%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $78.7M | $75.5M |
| 净利润 | $-70.0K | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | 2.0% | 22.7% |
| 净利率 | -0.1% | — |
| 营收同比 | 6.8% | 27.7% |
| 净利润同比 | -101.4% | — |
| 每股收益（稀释后） | $0.00 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTLPPBYI
| Q4 25 | $78.7M | $75.5M | ||
| Q3 25 | $80.9M | $54.5M | ||
| Q2 25 | $82.6M | $52.4M | ||
| Q1 25 | $75.4M | $46.0M | ||
| Q4 24 | $73.7M | $59.1M | ||
| Q3 24 | $70.8M | $80.5M | ||
| Q2 24 | $72.7M | $47.1M | ||
| Q1 24 | $67.9M | $43.8M |
净利润CTLPPBYI
| Q4 25 | $-70.0K | — | ||
| Q3 25 | $-919.0K | $8.8M | ||
| Q2 25 | $6.8M | $5.9M | ||
| Q1 25 | $49.2M | $3.0M | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $3.6M | $20.3M | ||
| Q2 24 | $2.2M | $-4.5M | ||
| Q1 24 | $4.7M | $-4.8M |
毛利率CTLPPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | 39.6% | 75.5% |
营业利润率CTLPPBYI
| Q4 25 | 2.0% | 22.7% | ||
| Q3 25 | 2.0% | 17.6% | ||
| Q2 25 | 6.3% | 12.7% | ||
| Q1 25 | 9.1% | 8.7% | ||
| Q4 24 | 8.4% | 22.6% | ||
| Q3 24 | 5.8% | 27.4% | ||
| Q2 24 | 4.9% | -4.6% | ||
| Q1 24 | 6.3% | -5.3% |
净利率CTLPPBYI
| Q4 25 | -0.1% | — | ||
| Q3 25 | -1.1% | 16.2% | ||
| Q2 25 | 8.3% | 11.2% | ||
| Q1 25 | 65.2% | 6.5% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 5.0% | 25.2% | ||
| Q2 24 | 3.0% | -9.6% | ||
| Q1 24 | 6.9% | -11.0% |
每股收益（稀释后）CTLPPBYI
| Q4 25 | $0.00 | $0.26 | ||
| Q3 25 | $-0.02 | $0.17 | ||
| Q2 25 | $0.10 | $0.12 | ||
| Q1 25 | $0.65 | $0.06 | ||
| Q4 24 | $0.07 | $0.40 | ||
| Q3 24 | $0.04 | $0.41 | ||
| Q2 24 | $0.03 | $-0.09 | ||
| Q1 24 | $0.06 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $53.0M | $97.5M |
| 总债务越低越好 | $37.7M | $22.7M |
| 股东权益账面价值 | $252.5M | $130.3M |
| 总资产 | $381.9M | $216.3M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资CTLPPBYI
| Q4 25 | $53.0M | $97.5M | ||
| Q3 25 | $55.0M | $94.4M | ||
| Q2 25 | $51.1M | $96.0M | ||
| Q1 25 | $46.3M | $93.2M | ||
| Q4 24 | $27.7M | $101.0M | ||
| Q3 24 | $33.1M | $96.7M | ||
| Q2 24 | $58.9M | $96.8M | ||
| Q1 24 | $50.2M | $107.2M |
总债务CTLPPBYI
| Q4 25 | $37.7M | $22.7M | ||
| Q3 25 | $38.3M | $34.0M | ||
| Q2 25 | $38.7M | $45.3M | ||
| Q1 25 | $39.2M | $56.7M | ||
| Q4 24 | $37.0M | $68.0M | ||
| Q3 24 | $37.3M | $79.3M | ||
| Q2 24 | $37.5M | $90.7M | ||
| Q1 24 | $38.1M | $102.0M |
股东权益CTLPPBYI
| Q4 25 | $252.5M | $130.3M | ||
| Q3 25 | $251.8M | $115.3M | ||
| Q2 25 | $251.0M | $104.7M | ||
| Q1 25 | $240.7M | $97.1M | ||
| Q4 24 | $190.1M | $92.1M | ||
| Q3 24 | $186.2M | $71.1M | ||
| Q2 24 | $181.7M | $48.5M | ||
| Q1 24 | $178.8M | $51.0M |
总资产CTLPPBYI
| Q4 25 | $381.9M | $216.3M | ||
| Q3 25 | $389.5M | $202.9M | ||
| Q2 25 | $381.9M | $194.9M | ||
| Q1 25 | $370.5M | $196.2M | ||
| Q4 24 | $303.0M | $213.3M | ||
| Q3 24 | $312.1M | $220.7M | ||
| Q2 24 | $335.6M | $205.0M | ||
| Q1 24 | $319.9M | $214.1M |
负债/权益比CTLPPBYI
| Q4 25 | 0.15× | 0.17× | ||
| Q3 25 | 0.15× | 0.30× | ||
| Q2 25 | 0.15× | 0.43× | ||
| Q1 25 | 0.16× | 0.58× | ||
| Q4 24 | 0.19× | 0.74× | ||
| Q3 24 | 0.20× | 1.12× | ||
| Q2 24 | 0.21× | 1.87× | ||
| Q1 24 | 0.21× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.1M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $-614.0K | $14.4M |
| 自由现金流率自由现金流/营收 | -0.8% | 19.1% |
| 资本支出强度资本支出/营收 | 4.8% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $25.8M | $41.7M |
8季度趋势，按日历期对齐
经营现金流CTLPPBYI
| Q4 25 | $3.1M | $14.4M | ||
| Q3 25 | $7.0M | $9.7M | ||
| Q2 25 | $9.4M | $14.1M | ||
| Q1 25 | $22.4M | $3.6M | ||
| Q4 24 | $522.0K | $15.6M | ||
| Q3 24 | $-12.0M | $11.0M | ||
| Q2 24 | $14.3M | $1.0M | ||
| Q1 24 | $14.7M | $11.2M |
自由现金流CTLPPBYI
| Q4 25 | $-614.0K | $14.4M | ||
| Q3 25 | $3.5M | $9.7M | ||
| Q2 25 | $4.3M | $14.1M | ||
| Q1 25 | $18.6M | $3.6M | ||
| Q4 24 | $-3.8M | $15.6M | ||
| Q3 24 | $-15.8M | $11.0M | ||
| Q2 24 | $8.5M | $1.0M | ||
| Q1 24 | $11.4M | — |
自由现金流率CTLPPBYI
| Q4 25 | -0.8% | 19.1% | ||
| Q3 25 | 4.4% | 17.7% | ||
| Q2 25 | 5.3% | 26.8% | ||
| Q1 25 | 24.6% | 7.7% | ||
| Q4 24 | -5.1% | 26.4% | ||
| Q3 24 | -22.3% | 13.7% | ||
| Q2 24 | 11.7% | 2.1% | ||
| Q1 24 | 16.9% | — |
资本支出强度CTLPPBYI
| Q4 25 | 4.8% | 0.0% | ||
| Q3 25 | 4.2% | 0.0% | ||
| Q2 25 | 6.2% | 0.0% | ||
| Q1 25 | 5.1% | 0.1% | ||
| Q4 24 | 5.8% | 0.0% | ||
| Q3 24 | 5.4% | 0.0% | ||
| Q2 24 | 7.9% | 0.0% | ||
| Q1 24 | 4.8% | 0.0% |
现金转化率CTLPPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | 1.38× | 2.41× | ||
| Q1 25 | 0.46× | 1.21× | ||
| Q4 24 | 0.10× | — | ||
| Q3 24 | -3.36× | 0.54× | ||
| Q2 24 | 6.47× | — | ||
| Q1 24 | 3.16× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTLP
| Transaction Processing | $47.9M | 61% |
| Subscription Revenue | $21.8M | 28% |
| Products | $9.0M | 11% |
PBYI
暂无分部数据
